Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 42 entries
View as:

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Phase: N/A Priority: Normal
NCT ID: NCT02757989 Org: User:
Start: 05/31/16 End: 06/07/24 Due: 06/07/25

GFM-Acadesine: A Phase I-II Trial of Acadesine

Phase: N/A Priority: Normal
NCT ID: NCT01813838 Org: User:
Start: 06/30/13 End: 06/30/15 Due: 06/30/16

A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients

Phase: N/A Priority: Normal
NCT ID: NCT02323139 Org: User:
Start: 02/10/15 End: 08/01/18 Due: 08/01/19

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Phase: N/A Priority: Normal
NCT ID: NCT00455910 Org: User:
Start: 01/31/03 End: 03/31/07 Due: 03/31/08

Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT01305135 Org: User:
Start: 12/30/10 End: 05/09/16 Due: 05/09/17

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Phase: N/A Priority: Normal
NCT ID: NCT00776503 Org: User:
Start: 05/31/08 End: 11/30/11 Due: 11/30/12

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT00443339 Org: User:
Start: 12/31/06 End: 07/31/08 Due: 07/31/09

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT03454984 Org: User:
Start: 11/30/18 End: 03/31/22 Due: 03/31/23

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Phase: N/A Priority: Normal
NCT ID: NCT01718379 Org: User:
Start: 07/31/10 End: 06/30/16 Due: 06/30/17

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Phase: N/A Priority: Normal
NCT ID: NCT01015352 Org: User:
Start: 02/28/09 End: 03/31/14 Due: 03/31/15

Erlotinib in Higher Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01085838 Org: User:
Start: 07/31/10 End: 03/31/14 Due: 03/31/15

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS

Phase: N/A Priority: Normal
NCT ID: NCT01718366 Org: User:
Start: 02/28/13 End: 02/28/19 Due: 02/28/20

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Phase: N/A Priority: Normal
NCT ID: NCT00446303 Org: User:
Start: 07/31/06 End: 07/31/10 Due: 07/31/11

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02938858 Org: User:
Start: 10/31/15 End: 10/31/22 Due: 10/31/23

CPX-351 in Higher Risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT04273802 Org: User:
Start: 04/29/20 End: 07/06/22 Due: 07/06/23

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Phase: N/A Priority: Normal
NCT ID: NCT02197676 Org: User:
Start: 08/04/14 End: 04/23/18 Due: 04/23/19

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT04857645 Org: User:
Start: 06/22/21 End: 04/22/25 Due: 04/22/26

Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00411905 Org: User:
Start: 06/01/06 End: 08/01/11 Due: 08/01/12

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT06670222 Org: User:
Start: 05/31/25 End: 06/30/27 Due: 06/30/28

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Phase: N/A Priority: Normal
NCT ID: NCT00885508 Org: User:
Start: 02/28/09 End: 12/31/15 Due: 12/31/16

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Phase: N/A Priority: Normal
NCT ID: NCT05226455 Org: User:
Start: 11/23/22 End: 09/01/27 Due: 09/01/28

A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT02323178 Org: User:
Start: 08/07/14 End: 04/30/21 Due: 04/30/22

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT01305460 Org: User:
Start: 07/05/11 End: 11/16/15 Due: 11/16/16

A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders

Phase: N/A Priority: Normal
NCT ID: NCT02985190 Org: User:
Start: 01/26/17 End: 08/30/22 Due: 08/30/23

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Phase: N/A Priority: Normal
NCT ID: NCT03223961 Org: User:
Start: 03/26/18 End: 10/01/28 Due: 10/01/29